Paras M Patel, MD | |
1400 S Main St Ste 501, Fort Worth, TX 76104-4909 | |
(817) 702-8400 | |
Not Available |
Full Name | Paras M Patel |
---|---|
Gender | Male |
Speciality | Critical Care (intensivists) |
Experience | 20 Years |
Location | 1400 S Main St Ste 501, Fort Worth, Texas |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1497926737 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RC0200X | Internal Medicine - Critical Care Medicine | R7848 (Texas) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Jps Health Network | Fort worth, TX | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Acclaim Physician Group Inc | 4587963582 | 439 |
News Archive
Rose Medical Center is the first hospital in Colorado to perform a new and innovative procedure for patients with peripheral arterial disease (PAD). Utilizing the Lutonix 035 Drug Coated Balloon PTA Catheter, surgeons are able to perform a balloon angioplasty in patients with PAD using a special drug-coated balloon (DCB) that delivers a small amount of medication to the inside walls of the diseased portion of the artery.
A study by University of Cincinnati researchers and four Italian institutions reviewing neuroimaging and neurological symptoms in patients with COVID-19 may shed light on the virus's impact on the central nervous system.
The American Board of Internal Medicine, as part of its "Choosing Wisely" campaign, expanded the number of medical societies recommending caution before certain tests and procedures are ordered.
Octapharma AG is leading an international initiative focused on confronting the major risk associated with hemophilia A therapy - anti-factor VIII (FVIII) antibodies, also known as inhibitors. This initiative, combined with Octapharma's efforts to pursue the first recombinant FVIII therapy produced from a human cell line, could dramatically impact the treatment of an estimated one in every 5,000 to 10,000 men born with hemophilia A worldwide.
› Verified 3 days ago
Entity Name | Acclaim Physician Group Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1780076562 PECOS PAC ID: 4587963582 Enrollment ID: O20160426000707 |
News Archive
Rose Medical Center is the first hospital in Colorado to perform a new and innovative procedure for patients with peripheral arterial disease (PAD). Utilizing the Lutonix 035 Drug Coated Balloon PTA Catheter, surgeons are able to perform a balloon angioplasty in patients with PAD using a special drug-coated balloon (DCB) that delivers a small amount of medication to the inside walls of the diseased portion of the artery.
A study by University of Cincinnati researchers and four Italian institutions reviewing neuroimaging and neurological symptoms in patients with COVID-19 may shed light on the virus's impact on the central nervous system.
The American Board of Internal Medicine, as part of its "Choosing Wisely" campaign, expanded the number of medical societies recommending caution before certain tests and procedures are ordered.
Octapharma AG is leading an international initiative focused on confronting the major risk associated with hemophilia A therapy - anti-factor VIII (FVIII) antibodies, also known as inhibitors. This initiative, combined with Octapharma's efforts to pursue the first recombinant FVIII therapy produced from a human cell line, could dramatically impact the treatment of an estimated one in every 5,000 to 10,000 men born with hemophilia A worldwide.
› Verified 3 days ago
Entity Name | Questcare Pulmonary In-patient Services Pllc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1629553375 PECOS PAC ID: 0244577385 Enrollment ID: O20190128000476 |
News Archive
Rose Medical Center is the first hospital in Colorado to perform a new and innovative procedure for patients with peripheral arterial disease (PAD). Utilizing the Lutonix 035 Drug Coated Balloon PTA Catheter, surgeons are able to perform a balloon angioplasty in patients with PAD using a special drug-coated balloon (DCB) that delivers a small amount of medication to the inside walls of the diseased portion of the artery.
A study by University of Cincinnati researchers and four Italian institutions reviewing neuroimaging and neurological symptoms in patients with COVID-19 may shed light on the virus's impact on the central nervous system.
The American Board of Internal Medicine, as part of its "Choosing Wisely" campaign, expanded the number of medical societies recommending caution before certain tests and procedures are ordered.
Octapharma AG is leading an international initiative focused on confronting the major risk associated with hemophilia A therapy - anti-factor VIII (FVIII) antibodies, also known as inhibitors. This initiative, combined with Octapharma's efforts to pursue the first recombinant FVIII therapy produced from a human cell line, could dramatically impact the treatment of an estimated one in every 5,000 to 10,000 men born with hemophilia A worldwide.
› Verified 3 days ago
Mailing Address | Practice Location Address |
---|---|
Paras M Patel, MD Po Box 732973, Dallas, TX 75373-2973 Ph: (817) 702-8450 | Paras M Patel, MD 1400 S Main St Ste 501, Fort Worth, TX 76104-4909 Ph: (817) 702-8400 |
News Archive
Rose Medical Center is the first hospital in Colorado to perform a new and innovative procedure for patients with peripheral arterial disease (PAD). Utilizing the Lutonix 035 Drug Coated Balloon PTA Catheter, surgeons are able to perform a balloon angioplasty in patients with PAD using a special drug-coated balloon (DCB) that delivers a small amount of medication to the inside walls of the diseased portion of the artery.
A study by University of Cincinnati researchers and four Italian institutions reviewing neuroimaging and neurological symptoms in patients with COVID-19 may shed light on the virus's impact on the central nervous system.
The American Board of Internal Medicine, as part of its "Choosing Wisely" campaign, expanded the number of medical societies recommending caution before certain tests and procedures are ordered.
Octapharma AG is leading an international initiative focused on confronting the major risk associated with hemophilia A therapy - anti-factor VIII (FVIII) antibodies, also known as inhibitors. This initiative, combined with Octapharma's efforts to pursue the first recombinant FVIII therapy produced from a human cell line, could dramatically impact the treatment of an estimated one in every 5,000 to 10,000 men born with hemophilia A worldwide.
› Verified 3 days ago
Charles A Carlton, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1622 8th Avenue, Suite 110, Fort Worth, TX 76104 Phone: 817-926-2561 Fax: 817-921-3708 | |
Paul J Garcia, DO Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 5701 Bryant Irvin Rd, Suite 302, Fort Worth, TX 76132 Phone: 817-294-9000 Fax: 817-294-9010 | |
Stevan A Gonzalez, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1250 8th Ave, Suite 515, Fort Worth, TX 76104 Phone: 817-922-4675 Fax: 817-922-4645 | |
Jeremy Aaron Ross, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 800 W Magnolia Ave, Fort Worth, TX 76104 Phone: 817-759-7000 Fax: 817-759-7027 | |
Elie B Choufani, M.D. Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 601 W Terrell Ave, Fort Worth, TX 76104 Phone: 817-852-8305 | |
Syed Hadi Jafri, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1300 W Terrell Ave Fl 2, Fort Worth, TX 76104 Phone: 817-820-4906 Fax: 817-820-4815 | |
Cheryl K Mcdonald, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1125 College Ave, Fort Worth, TX 76104 Phone: 817-810-9810 Fax: 817-810-9815 |